Cell and Organ Transplantology. 2015; 3(2):150-154.
DOI: 10.22494/COT.V3I2.11
Dynamics of CD133+ cells in cultures of glioma c6 and fetal rat brain under the neurogenic cells supernatant influence
Liubich L. D., Lisyany N. I., Semenova V. M., Stayno L. P.
A. P. Romodanov State Institute of Neurosurgery NAMS of Ukraine, Kyiv, Ukraine
Abstract
Cellular and molecular similarities between brain tumor stem cells (BTSCs) and normal neurogenic stem cells (NSCs) motivate the search for new methods of treatment of malignant glioma using NSCs. CD133 molecule could be one of the most typical markers of BTSCs and considered as a target for therapy of brain tumors.
The aim of this study was to evaluate the effect of rat neurogenic cells supernatant (NCsS) on the content of CD133+ cells in glioma C6 cell cultures.
Materials and methods. The cells of rat brain glioma C6 were used as the source for the cultivation; for comparative assessment of tested compound impact on the intact nervous system the fetal rat brain cells on 14th (E14) day of gestation were used. The study was performed in control cultures under standard culture conditions without NCsS adding and tested cultures with adding NCsS (0.10 mg/ml of protein) for 48 hours. NCsS was received from suspensions of rat brain neurogenic cells (E14).
Results. CD133-positive cells were 12.05 ± 4.77 % of the total number of cells in C6 glioma culture and 37.36 ± 12.33 % of the total number of cells in fetal rat brain culture. CD133-positive cells had a smaller size than negative cells (average values of cross-sectional area of cells and nucleus) and greater nuclear-cytoplasmic ratio. The cell and nucleus sizes of CD133-positive cells in cell cultures of fetal rat brain were twice larger than sizes of such cells in cultures of glioma C6.
Under the conditions of NCsS for 48 hours the reducing in the number of CD133-positive cells in rat glioma C6 cell cultures (2.88 ± 0.41 %) and lack of such effects in cell cultures of fetal rat brain (E14) were found.
Conclusion. The morphological differences of CD133-positive cells in glioma C6 cultures and in cell cultures of fetal rat brain (E14) were detected. The decrease of CD133-positive cells in glioma C6 cells culture under the influence of neurogenic cells supernatant was shown.
Key words: glioma C6, fetal rat brain cell culture, neurogenic cells supernatant, CD133
Full Text PDF (eng) Full Text PDF (ua)1. Angelastro JM, Lame MW. Overexpression of CD133 promotes drug resistance in C6 glioma cells. Mol. Cancer Res. 2010; 8(8):1105–1115. https://doi.org/10.1158/1541-7786.MCR-09-0383 PMid:20663862 PMCid:PMC2923683 |
||||
2. Brescia P, Richichi Ch, Pehcci G. Current strategies for identification of glioma stem cells: Adequate or unsatisfactory? J. Oncol. 2012. Available: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3366252/pdf/JO2012-376894.pdf. | ||||
3. Sanai N, Alvarez-Buylla A, Berger MS. Neural stem cells and the origin of gliomas. N. Engl. J. Med. 2005; 353(8):811-822. https://doi.org/10.1056/NEJMra043666 PMid:16120861 |
||||
4. Shervington A, Lu C, Shervington A. Expression of multidrug resistance genes in normal and cancer stem cells. Cancer Invest. 2008; 26(5):535-542. https://doi.org/10.1080/07357900801904140 PMid:18568776 |
||||
5. Shen G, Shen F, Shi Z, et al. Identification of cancer stem-like cells in C6 glioma cell line and the limitation of current identification methods. In Vitro Cell Dev. Biol. Anim. 2008; 44(7):280-289. https://doi.org/10.1007/s11626-008-9115-z PMid:18594936 |
||||
6. Perez Castillo A, Aguilar-Morante D, Morales-Garcia JA, et al. Cancer stem cells and brain tumors. Clin. Transl. Oncol. 2008; 10(5):262-267. https://doi.org/10.1007/s12094-008-0195-8 PMid:18490242 |
||||
7. Mizrak D, Brittan M, Alison MR. CD133 molecule of the moment. J. Pathol. 2008; 214(1):3-9. https://doi.org/10.1002/path.2283 PMid:18067118 |
||||
8. Ahmed AU, Ulasov IV, Mercer RW, et al. Maintaining and loading neural stem cells for delivery of oncolytic adenovirus to brain tumors. Methods Mol. Biol. 2012; 797:97-109. https://doi.org/10.1007/978-1-61779-340-0_8 PMid:21948472 |
||||
9. Khosh N, Brown CE, Aboody KS, et al. Contact and encirclement of glioma cells in vitro is an intrinsic behavior of a clonal human neural stem cell line. PLoS ONE. 2012; 7(12):e51859. Available: http://www.jourlib.org/paper/3003453. https://doi.org/10.1371/journal.pone.0051859 PMid:23240066 PMCid:PMC3519902 |
||||
10. Aboody KS, Najbauer J, Metz MZ, et al. Neural Stem Cell–Mediated Enzyme/Prodrug Therapy for Glioma: Preclinical Studies. Sci. Transl. Med. 2013; 5(184):184-189. https://doi.org/10.1126/scitranslmed.3005365 PMid:23658244 PMCid:PMC3864887 |
||||
11. Bovenberg MS, Degeling MH, Tannous BA. Advances in stem cell therapy against gliomas. Trends Mol. Med. 2013; 19(5):281-291. https://doi.org/10.1016/j.molmed.2013.03.001 PMid:23537753 |
||||
12. Morshed RA, Gutova M, Juliano J, et al. Analysis of glioblastoma tumor coverage by oncolytic virus-loaded neural stem cells using MRI-based tracking and histological reconstruction. Cancer Gene Therapy. 2015; 22:55–61. https://doi.org/10.1038/cgt.2014.72 PMid:25525033 PMCid:PMC4293243 |
||||
13. Stem cell therapeutics for cancer / Shah Kh.(ed.). Wiley Blackwell, 2013. 304 p. | ||||
14. Lisyany NI, Liubich LD. Doslidzhennja vplyvu supernatantu nejrogennyh klityn na puhlynoindukujuchu zdatnist’ klityn gliomy 101.8 u shhuriv [Effects of the neurogenic cells supernatant on the tumor-inducing ability of glioma 101.8 in rats]. Klitynna ta organna transplantologija – Cell and Organ Transplantology. 2015; 3(1):52-61. | ||||
15. Liubich LD, Semenova VM, Stayno LP. Influence of rat progenitor neurogenic cells supernatant on glioma 101.8 cells in vitro. Biopolymers and Cell. 2015; 31(3):200–208. https://doi.org/10.7124/bc.0008E1 |
||||
16. Bozhkova VP, Brezhestovsky PD, Zhuravlev VP, et al. Rukovodstvo po kul’tivirovaniju nervnoj tkani. Metody. Tehnika. Problemy [Guide culturing neural tissue. Methods. Equipment. Problems ] Moskva: Nauka – Moskow: Science, 1988. 317 p. | ||||
17. Chen R, Nishimura MC, Bumbaca SM, et al. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell. 2010; 17(4):362–375. https://doi.org/10.1016/j.ccr.2009.12.049 PMid:20385361 |
||||
18. Klassen HJ, Imfeld KL, Kirov II, et al. Expression of cytokines by multipotent neural progenitor cells. Cytokine. 2003; 22(3-4):101-106. https://doi.org/10.1016/S1043-4666(03)00120-0 |
||||
19. Liu J, Götherström C, Forsberg M, et al. Human neural stem/progenitor cells derived from embryonic stem cells and fetal nervous system present differences in immunogenicity and immunomodulatory potentials in vitro. Stem Cell Res. 2013; 10(3):325-337. https://doi.org/10.1016/j.scr.2013.01.001 PMid:23416350 |
||||
20. Chen HC, Ma HI, Sytwu KH, et al. Neural stem cells secrete factors that promote auditory cell proliferation via a leukemia inhibitory factor signaling pathway. J. Neurosci. Res. 2010; 88(15):3308-3318. https://doi.org/10.1002/jnr.22492 PMid:20882565 |
||||
21. Kaminska B, Kocyk M, Kijewska M. TGF beta signaling and its role in glioma pathogenesis. Adv.Exp.Med.Biol. 2013; 986:171-187. https://doi.org/10.1007/978-94-007-4719-7_9 PMid:22879069 |
||||
22. Zhang J, Yang W, Zhao D, et al. Correlation between TSP-1, TGF-β and PPAR-γ expression levels and glioma microvascular density. Oncol. Lett. 2014; 7(1):95-100. PMid:24348828 |
||||
23. Dubrovska AM, Souchelnytskyi SS. Low-density microarray analysis of TGF1-dependent cell cycle regulation in human breast adenocarcinoma MCG7 cell line. Biopolymers and Cell. 2014; 30(2):107-117. https://doi.org/10.7124/bc.000888 |
||||
24. Binder DK, Scharfman HE. Brain-derived Neurotrophic Factor. Growth Factors. 2004; 22(3):123-131. https://doi.org/10.1080/08977190410001723308 PMid:15518235 PMCid:PMC2504526 |
Liubich LD, Lisyany NI, Semenova VM, Stayno LP. Dynamics of CD133+ cells in cultures of glioma C6 and fetal rat brain under the neurogenic cells supernatant influence. Cell and Organ Transplantology. 2015; 3(2):150-154. doi: 10.22494/COT.V3I2.11
Is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.